優質白內障手術 (PCS) 市場 (2023)：前 13 個國家分析 (2022-2028)

本報告考察了高級白內障手術 (PCS) 市場，對全球 PCS 手術和產品收入進行了分析，確定了主要趨勢，並討論了未來成功的關鍵因素。它還包括以下資訊：

• 老花矯正、複曲面、中間節段優化、術後可調IOL、FLACS雷射、FLACS弓形切口、手法角膜緣鬆弛切口、準分子IOL增強術
• 前 13 個國家（美國、日本、中國、巴西、韓國、印度、德國、法國、加拿大、澳洲、西班牙、義大利、英國）PCS 市場概況及詳細概況
• 每個國家的執行摘要
• 公立和私立白內障手術選擇的成本分析：按國家/地區
• 預測 PCS 手術和製造商收入：按國家/地區
• 預測來自 PCS 程式的提供者收入：按國家/地區
• 各主要國家中純白內障外科醫生、白內障/屈光外科醫生和僅屈光外科醫生實施的 PCS 手術的百分比
• 各國及全球PCS市場廠商收入市場份額
• 最重要的 PCS 眼科醫院和診所清單：按國家/地區
• 按國家/地區劃分的最具影響力的 PCS 關鍵意見領袖 (KOL) 名單
• 接下來 6 個最重要的 PCS 國家列表（按規模排名）

What's New:

The new "2023 Premium Cataract Surgery Market Report" now features historical analysis of PC-IOL and toric IOL penetration, along with five-year forecasts, for each of the 13 countries covered in the report. The report provides a projection for the impact of recent economics on each of these markets and the elderly populations that account for a majority of premium cataract procedures.

The report examines the strong growth that has occurred in cataract surgery in 2022 and 2023, eliminating much of the COVID-19 backlog. We provide a deeper analysis of the timing and dramatic impact of the loss of PC-IOL and FLACS reimbursement in South Korea.

The new report also features more than 20 premium IOL product surveys in the United States and Western Europe; lists the many new PC-IOLs launched at the 2023 ESCRS congress; and expands on the list of premium cataract surgery centers by country.

The "2023 Premium Cataract Surgery Market Report" is designed to provide insights into the most important premium cataract surgery (PCS) markets in the world. We've selected and profiled 13 countries that collectively account for 84 percent of global PCS manufacturer revenue and provided a deep dive into each of these markets. Ranked by 2022 PCS manufacturer revenue, they are: the United States, China, South Korea, Japan, Brazil, Germany, Canada, Australia, France, India, Spain, the UK, and Italy.

For each of these countries, the report focuses on specific characteristics considered vital to the understanding of the opportunities in each country for companies planning to market premium cataract surgery devices or looking to assess the value of each market.

Contents:

The report offers an in-depth examination of the 2023 premium cataract surgery (PCS) market. It includes analysis of the global PCS procedure and product revenue, identification of important trends, and discussion of key factors for future success. The following information is also included:

• Presbyopia-correcting, toric, intermediate-optimized, and post-op adjustable IOLs, FLACS lasers, FLACS arcuate incisions, manual limbal relaxing incisions, and excimer IOL enhancements.

• Snapshots and in-depth profiles of the top 13 PCS markets: the US, Japan, China, Brazil, South Korea, India, Germany, France, Canada, Australia, Spain, Italy, and the UK.

• Individual country executive summary.

• Analysis of the cost of public and private cataract surgery options by country.

• Forecasts for PCS procedures and manufacturer revenue by country.

• Forecasts for provider revenue resulting from PCS procedures by country.

• Percentage of PCS procedures performed in each key country by cataract-only, cataract/refractive, and refractive-only surgeons.

• Manufacturer revenue market shares of the PCS market in each country and globally.

• Listing of the most important PCS eye hospitals and clinics by country.

• Listing of the most influential PCS key opinion leaders (KOLs) by country.

• A list of the next six most important PCS countries ranked by size.

Author Profile:

William Freeman

Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.

Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.

CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.

In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.